Shots:

• NeoImmuneTech to sponsor the trial and BMS will supply Opdivo (nivolumab) for the use in the trial. Additionally- under Master Clinical Trial Collaboration Agreement- the first study will be focusing on gastric/GEJ/EAC cancers and the companies can evaluate additional combination trials in the future
• The goal of the collaboration is to evaluate preliminary anti-tumor activity of the combination of Opdivo + NT-I7 in P-II trial assessing the safety and tolerability to treat advanced or metastatic gastric- GEJ- or EAC in patients
• NT-I7 (also known as Hyleukin-7) is a long-acting human IL-7 and is evaluated in multiple clinical trials in solid tumors- and being planned for testing in hematologic malignancies and other immunology-focused indications

Click here ­to­ read full press release/ article 

Ref:  Business Wire  | Image: BMS